csirt@kutim:~/threat-intel/cve/CVE-2024-28864

Katalog CVE

CVSS 2.6 · Low EPSS 0,33%

Kerentanan Inefficient Regular Expression Complexity pada ilicmiljan secureprops. Skor CVSS 3.1 2.6 (Low) menurut github.com.

Deskripsi (NVD)

SecureProps is a PHP library designed to simplify the encryption and decryption of property data in objects. A vulnerability in SecureProps version 1.2.0 and 1.2.1 involves a regex failing to detect tags during decryption of encrypted data. This occurs when the encrypted data has been encoded with `NullEncoder` and passed to `TagAwareCipher`, and contains special characters such as `\n`. As a result, the decryption process is skipped since the tags are not detected. This causes the encrypted data to be returned in plain format. The vulnerability affects users who implement `TagAwareCipher` with any base cipher that has `NullEncoder` (not default). The patch for the issue has been released. Users are advised to update to version 1.2.2. As a workaround, one may use the default `Base64Encoder` with the base cipher decorated with `TagAwareCipher` to prevent special characters in the encrypted string from interfering with regex tag detection logic. This workaround is safe but may involve double encoding since `TagAwareCipher` uses `NullEncoder` by default.

Rincian

Terbit di NVD
18 Maret 2024
Terakhir diubah
17 Juni 2026
Status NVD
Analyzed
CVSS 3.1
2.6 (Low), sumber github.com
CVSS:3.1/AV:N/AC:H/PR:L/UI:R/S:U/C:L/I:N/A:N · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-1333: Inefficient Regular Expression Complexity
EPSS (30 hari)
0,33% peluang dieksploitasi; lebih tinggi dari 24,0% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
ilicmiljan secureprops Versi 1.2.0
ilicmiljan secureprops Versi 1.2.1

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.